Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a phase II clinical trial

BackgroundCombination of anti-PD-1 monoclonal antibody with chemotherapy has been widely used as a first-line treatment for metastatic esophageal squamous cell carcinoma (ESCC). However, the efficacy of this therapeutic combination as a neoadjuvant intervention for resectable ESCC remains inadequate...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Jincheng Guo, Chengrui Qiao, Jiabin Lu, Shiqing Yang, Boyi Zhang, Dongxia Tang, Hui Pang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Subjects:	esophageal squamous cell carcinoma neoadjuvant therapy sintilimab chemotherapy immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1486275/full